{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:31:31Z","timestamp":1773178291711,"version":"3.50.1"},"reference-count":56,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2013.0271","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:25:18Z","timestamp":1525253118000},"source":"Crossref","is-referenced-by-count":6,"title":["Fentanyl for the Treatment of Tumor-Related Breakthrough Pain"],"prefix":"10.3238","author":[{"given":"Helmar","family":"Bornemann-Cimenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mischa","family":"Wejbora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan S.","family":"Szilagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Sandner-Kiesling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2013,4,19]]},"reference":[{"key":"10.3238\/arztebl.2013.0271_ref1","doi-asserted-by":"crossref","unstructured":"Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G: The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009; 13: 331\u20138.","DOI":"10.1016\/j.ejpain.2008.06.014"},{"key":"10.3238\/arztebl.2013.0271_ref2","doi-asserted-by":"crossref","unstructured":"Hanks GW, Conno F, Cherny N, et al.: Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587\u201393.","DOI":"10.1054\/bjoc.2001.1680"},{"key":"10.3238\/arztebl.2013.0271_ref3","doi-asserted-by":"crossref","unstructured":"Mercadante S, Radbruch L, Caraceni A, et al.: Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94: 832\u20139.","DOI":"10.1002\/cncr.10249"},{"key":"10.3238\/arztebl.2013.0271_ref4","doi-asserted-by":"crossref","unstructured":"Streisand JB, Varvel JR, Stanski DR, et al.: Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75: 223\u20139.","DOI":"10.1097\/00000542-199108000-00009"},{"key":"10.3238\/arztebl.2013.0271_ref5","doi-asserted-by":"crossref","unstructured":"Grape S, Schug SA, Lauer S, Schug BS: Formulations of fentanyl for the management of pain. Drugs 2010; 70: 57\u201372.","DOI":"10.2165\/11531740-000000000-00000"},{"key":"10.3238\/arztebl.2013.0271_ref6","doi-asserted-by":"crossref","unstructured":"Coluzzi PH, Schwartzberg L, Conroy JD, et al.: Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91: 123\u201330.","DOI":"10.1016\/S0304-3959(00)00427-9"},{"key":"10.3238\/arztebl.2013.0271_ref7","doi-asserted-by":"crossref","unstructured":"Zeppetella G: Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008; 35: 563\u20137.","DOI":"10.1016\/j.jpainsymman.2007.06.012"},{"key":"10.3238\/arztebl.2013.0271_ref8","doi-asserted-by":"crossref","unstructured":"Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006(1): CD004311.","DOI":"10.1002\/14651858.CD004311.pub2"},{"key":"10.3238\/arztebl.2013.0271_ref9","doi-asserted-by":"crossref","unstructured":"Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G: Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007; 96: 1828\u201333.","DOI":"10.1038\/sj.bjc.6603811"},{"key":"10.3238\/arztebl.2013.0271_ref10","doi-asserted-by":"crossref","unstructured":"Hanks GW, Nugent M, Higgs CM, Busch MA: Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004; 18: 698\u2013704.","DOI":"10.1191\/0269216304pm966oa"},{"key":"10.3238\/arztebl.2013.0271_ref11","doi-asserted-by":"crossref","unstructured":"Payne R, Coluzzi P, Hart L, et al.: Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22: 575\u201383.","DOI":"10.1016\/S0885-3924(01)00306-2"},{"key":"10.3238\/arztebl.2013.0271_ref12","doi-asserted-by":"crossref","unstructured":"Nunez-Olarte JM, Alvarez-Jimenez P: Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Manage 2011; 42: e6\u20138.","DOI":"10.1016\/j.jpainsymman.2011.07.006"},{"key":"10.3238\/arztebl.2013.0271_ref13","doi-asserted-by":"crossref","unstructured":"Tennant F, Hermann L: Self-treatment with oral transmucosal fentanyl citrate to prevent emergency room visits for pain crises: patient self-reports of efficacy and utility. J Pain Palliat Care Pharmacother 2002; 16: 37\u201344.","DOI":"10.1080\/J354v16n03_04"},{"key":"10.3238\/arztebl.2013.0271_ref14","doi-asserted-by":"crossref","unstructured":"Burton AW, Driver LC, Mendoza TR, Syed G: Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series. Clin J Pain 2004; 20: 195\u20137.","DOI":"10.1097\/00002508-200405000-00011"},{"key":"10.3238\/arztebl.2013.0271_ref15","doi-asserted-by":"crossref","unstructured":"Ashburn MA, Slevin KA, Messina J, Xie F: The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011; 112: 693\u2013702.","DOI":"10.1213\/ANE.0b013e318209d320"},{"key":"10.3238\/arztebl.2013.0271_ref16","doi-asserted-by":"crossref","unstructured":"Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, Lennernas H: Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005; 59: 249\u201353.","DOI":"10.1111\/j.1365-2125.2004.02264.x"},{"key":"10.3238\/arztebl.2013.0271_ref17","doi-asserted-by":"crossref","unstructured":"Mercadante S.: Pharmacotherapy for breakthrough cancer pain. Drugs 2012; 72: 181\u201390.","DOI":"10.2165\/11597260-000000000-00000"},{"key":"10.3238\/arztebl.2013.0271_ref18","doi-asserted-by":"crossref","unstructured":"Finn AL, Vasisht N, Stark JG, Gever LN, Tagarro I: Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. Clin Drug Investig 2012; 32: 63\u201371.","DOI":"10.2165\/11594670-000000000-00000"},{"key":"10.3238\/arztebl.2013.0271_ref19","doi-asserted-by":"crossref","unstructured":"Vasisht N, Gever LN, Tagarro I, Finn AL: Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29: 647\u201354.","DOI":"10.2165\/11315300-000000000-00000"},{"key":"10.3238\/arztebl.2013.0271_ref20","doi-asserted-by":"crossref","unstructured":"Vasisht N, Gever LN, Tagarro I, Finn AL: Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010; 11: 1017\u201323.","DOI":"10.1111\/j.1526-4637.2010.00875.x"},{"key":"10.3238\/arztebl.2013.0271_ref21","doi-asserted-by":"crossref","unstructured":"Prommer E, Thompson L: Intranasal fentanyl for pain control: current status with a focus on patient considerations. Patient Prefer Adherence 2011; 5: 157\u201364.","DOI":"10.2147\/PPA.S7665"},{"key":"10.3238\/arztebl.2013.0271_ref22","doi-asserted-by":"crossref","unstructured":"Mercadante S, Radbruch L, Davies A, et al.: A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009; 25: 2805\u201315.","DOI":"10.1185\/03007990903336135"},{"key":"10.3238\/arztebl.2013.0271_ref23","doi-asserted-by":"crossref","unstructured":"Leppert W: Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Manag Res 2010; 2: 225\u201332.","DOI":"10.2147\/CMAR.S7926"},{"key":"10.3238\/arztebl.2013.0271_ref24","doi-asserted-by":"crossref","unstructured":"Vissers D, Stam W, Nolte T, Lenre M, Jansen J: Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010; 26: 1037\u201345.","DOI":"10.1185\/03007991003694340"},{"key":"10.3238\/arztebl.2013.0271_ref25","doi-asserted-by":"crossref","unstructured":"Watts P, Smith A: PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 2009; 6: 543\u201352.","DOI":"10.1517\/17425240902939135"},{"key":"10.3238\/arztebl.2013.0271_ref26","unstructured":"Joppich R, Poels M: Opioide \u2013 Was bringen neue Wirkstoffe und Applikationsformen? In: Daff (ed.): Refresher Course Nr. 37\/2011 \u2013 Aktuelles Wissen f\u00fcr An\u00e4sthesisten. Ebelsbach, Deutschland: Aktiv Druck & Verlag GmbH 2001; 277\u201390."},{"key":"10.3238\/arztebl.2013.0271_ref27","doi-asserted-by":"crossref","unstructured":"Davies A, Sitte T, Elsner F, et al.: Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011; 41: 358\u201366.","DOI":"10.1016\/j.jpainsymman.2010.11.004"},{"key":"10.3238\/arztebl.2013.0271_ref28","doi-asserted-by":"crossref","unstructured":"Fallon M, Reale C, Davies A, et al.: Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 2011; 9: 224\u201331.","DOI":"10.1016\/j.suponc.2011.07.004"},{"key":"10.3238\/arztebl.2013.0271_ref29","doi-asserted-by":"crossref","unstructured":"Radbruch L, Torres LM, Ellershaw JE, et al.: Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer 2012; 20: 565\u201373.","DOI":"10.1007\/s00520-011-1124-x"},{"key":"10.3238\/arztebl.2013.0271_ref30","doi-asserted-by":"crossref","unstructured":"Davis MP: Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother 2011; 11: 1197\u2013216.","DOI":"10.1586\/ern.11.63"},{"key":"10.3238\/arztebl.2013.0271_ref31","doi-asserted-by":"crossref","unstructured":"Passik SD, Messina J, Golsorkhi A, Xie F: Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage 2011; 41: 116\u201325.","DOI":"10.1016\/j.jpainsymman.2010.03.012"},{"key":"10.3238\/arztebl.2013.0271_ref32","doi-asserted-by":"crossref","unstructured":"Fine PG, Narayana A, Passik SD: Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. Pain Med 2010; 11: 1024\u201336.","DOI":"10.1111\/j.1526-4637.2010.00891.x"},{"key":"10.3238\/arztebl.2013.0271_ref33","doi-asserted-by":"crossref","unstructured":"Portenoy RK, Messina J, Xie F, Peppin J: Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007; 23: 223\u201333.","DOI":"10.1185\/030079906X162818"},{"key":"10.3238\/arztebl.2013.0271_ref34","doi-asserted-by":"crossref","unstructured":"Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 588\u2013601.","DOI":"10.1016\/j.clinthera.2007.04.007"},{"key":"10.3238\/arztebl.2013.0271_ref35","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Singh V, Caraway DL, Benyamin RM: Breakthrough pain in chronic non-cancer pain: fact, fiction, or abuse. Pain Physician 2011; 14: E103\u201317.","DOI":"10.36076\/ppj.2011\/14\/E103"},{"key":"10.3238\/arztebl.2013.0271_ref36","doi-asserted-by":"crossref","unstructured":"Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP: An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health 2011; 14: 274\u201381.","DOI":"10.1016\/j.jval.2010.09.007"},{"key":"10.3238\/arztebl.2013.0271_ref37","unstructured":"Slatkin NE, Xie F, Messina J, Segal TJ: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007; 5: 327\u201334."},{"key":"10.3238\/arztebl.2013.0271_ref38","doi-asserted-by":"crossref","unstructured":"Mercadante S: The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 2011; 80: 460\u20135.","DOI":"10.1016\/j.critrevonc.2010.12.002"},{"key":"10.3238\/arztebl.2013.0271_ref39","doi-asserted-by":"crossref","unstructured":"Portenoy RK, Payne R, Coluzzi P, et al.: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303\u201312.","DOI":"10.1016\/S0304-3959(98)00179-1"},{"key":"10.3238\/arztebl.2013.0271_ref40","doi-asserted-by":"crossref","unstructured":"Christie JM, Simmonds M, Patt R, et al.: Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998; 16: 3238\u201345.","DOI":"10.1200\/JCO.1998.16.10.3238"},{"key":"10.3238\/arztebl.2013.0271_ref41","doi-asserted-by":"crossref","unstructured":"Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129\u201334.","DOI":"10.1016\/S0304-3959(99)00006-8"},{"key":"10.3238\/arztebl.2013.0271_ref42","doi-asserted-by":"crossref","unstructured":"Zeppetella G: Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med 2011; 25: 516\u201324.","DOI":"10.1177\/0269216310385601"},{"key":"10.3238\/arztebl.2013.0271_ref43","doi-asserted-by":"crossref","unstructured":"Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006(1): CD004311.","DOI":"10.1002\/14651858.CD004311.pub2"},{"key":"10.3238\/arztebl.2013.0271_ref44","doi-asserted-by":"crossref","unstructured":"Caraceni A, Bertetto O, Labianca R, et al.: Episodic (Breakthrough) Pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI-Italian Questionnaire for Intense Episodic Pain. J Pain Symptom Manage 2012; 43: 833\u201341.","DOI":"10.1016\/j.jpainsymman.2011.05.018"},{"key":"10.3238\/arztebl.2013.0271_ref45","doi-asserted-by":"crossref","unstructured":"Caraceni A, Martini C, Zecca E, et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004; 18: 177\u201383.","DOI":"10.1191\/0269216304pm890oa"},{"key":"10.3238\/arztebl.2013.0271_ref46","doi-asserted-by":"crossref","unstructured":"Hwang SS, Chang VT, Kasimis B: Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003; 101: 55\u201364.","DOI":"10.1016\/S0304-3959(02)00293-2"},{"key":"10.3238\/arztebl.2013.0271_ref47","doi-asserted-by":"crossref","unstructured":"Portenoy RK, Hagen NA: Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273\u201381.","DOI":"10.1016\/0304-3959(90)90004-W"},{"key":"10.3238\/arztebl.2013.0271_ref48","doi-asserted-by":"crossref","unstructured":"Zeppetella G, O\u2019Doherty CA, Collins S: Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000; 20: 87\u201392.","DOI":"10.1016\/S0885-3924(00)00161-5"},{"key":"10.3238\/arztebl.2013.0271_ref49","doi-asserted-by":"crossref","unstructured":"Kleeberg UR, Filbet M, Zeppetella G: Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 2011; 11: 185\u201390.","DOI":"10.1111\/j.1533-2500.2010.00414.x"},{"key":"10.3238\/arztebl.2013.0271_ref50","doi-asserted-by":"crossref","unstructured":"Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G: Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992; 213: 219\u201325.","DOI":"10.1016\/0014-2999(92)90685-W"},{"key":"10.3238\/arztebl.2013.0271_ref51","doi-asserted-by":"crossref","unstructured":"Trescot AM, Datta S, Lee M, Hansen H: Opioid pharmacology. Pain Physician 2008; 11(2 Suppl): S133\u201353.","DOI":"10.36076\/ppj.2008\/11\/S133"},{"key":"10.3238\/arztebl.2013.0271_ref52","doi-asserted-by":"crossref","unstructured":"Stanley TH: Fentanyl. J Pain Symptom Manage 2005; 29(5 Suppl): 67\u201371.","DOI":"10.1016\/j.jpainsymman.2005.01.009"},{"key":"10.3238\/arztebl.2013.0271_ref53","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft: Die unkritische Anwendung von Fentanylpflastern erh\u00f6ht das Risiko f\u00fcr schwerwiegende Nebenwirkungen. Dtsch Arztebl 2012; 109(14): A 724\u20135."},{"key":"10.3238\/arztebl.2013.0271_ref54","doi-asserted-by":"crossref","unstructured":"Prommer E: The role of fentanyl in cancer-related pain. J Palliat Med 2009; 12: 947\u201354.","DOI":"10.1089\/jpm.2009.0051"},{"key":"10.3238\/arztebl.2013.0271_ref55","doi-asserted-by":"crossref","unstructured":"Mandel L, Carunchio MJ: Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. J Am Dent Assoc 2011; 142: 406\u20139.","DOI":"10.14219\/jada.archive.2011.0195"},{"key":"10.3238\/arztebl.2013.0271_ref56","doi-asserted-by":"crossref","unstructured":"Darwis M, Kirby M, Robertson P, Jr., Tracewell W Jr., Jiang JG: Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007; 47: 343\u201350.","DOI":"10.1177\/0091270006297749"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:38:56Z","timestamp":1638797936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,19]]},"references-count":56,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2013.0271","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,19]]}}}